CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO IRONWOOD PHARMACEUTICALS, INC. IF PUBLICLY DISCLOSED. AMENDED AND RESTATED LICENSE...License Agreement • August 1st, 2019 • Ironwood Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”), entered into on this 1st day of August, 2019 (the “Amendment Date”) by and between Ironwood Pharmaceuticals, Inc., a Delaware corporation (“Ironwood”) and Astellas Pharma Inc., a corporation organized under the laws of Japan (“Astellas”), hereby amends and restates that certain License Agreement entered into by and between Ironwood and Astellas on November 10, 2009 (the “Effective Date”), as amended by Ironwood and Astellas pursuant to (a) that certain 1st Amendment to License Agreement, dated as of March 21, 2013 and (b) that certain 2nd Amendment to License Agreement, dated as of July 23, 2013 (the “Prior Agreement,” and as amended by this amendment, the “Agreement”). Ironwood and Astellas may be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
